Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

Renal insufficiency is common in patients with relapsed multiple myeloma and can often limit choice of therapy. Lenalidomide, a critical agent in the treatment of relapsed multiple myeloma, is renally cleared., This phase I/II trial evaluated the efficacy and safety of lenalidomide with dexamethason...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Cancer J
Asıl Yazarlar: Mikhael, Joseph, Manola, Judith, Dueck, Amylou C., Hayman, Suzanne, Oettel, Kurt, Kanate, Abraham S., Lonial, Sagar, Rajkumar, S. Vincent
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127323/
https://ncbi.nlm.nih.gov/pubmed/30190454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0110-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller